Urothelial cancer associated 1 (UCA1)

Urothelial cancer associated 1 (UCA1) is a prominent long non-coding RNA (lncRNA) that was originally identified as being highly overexpressed in bladder cancer. It plays a critical role as an oncogenic driver by acting as a molecular sponge for various tumor-suppressive microRNAs and by interacting with chromatin-remodeling complexes to regulate the cell cycle and metabolic reprogramming. UCA1 is particularly notable for its contribution to the 'Warburg effect' through the upregulation of hexokinase 2 and its ability to confer multi-drug resistance to a wide array of chemotherapeutic and targeted agents, including cisplatin and EGFR inhibitors. From a clinical perspective, UCA1 is a highly sensitive and specific diagnostic biomarker, especially when detected in the urine of patients with suspected urothelial carcinoma. Its strong correlation with poor prognosis, metastasis, and treatment failure across multiple solid tumors makes it an attractive therapeutic target. Current drug development efforts focus on RNA-interference (RNAi) and antisense oligonucleotide (ASO) strategies to silence UCA1 expression, thereby restoring drug sensitivity and inhibiting tumor progression. However, challenges remain regarding the efficient delivery of these RNA-targeted therapies and the potential for off-target effects.

Other names

CUDRCancer up-regulated drug resistantLINC00178NCRNA00178UCAT1Long intergenic non-protein coding RNA 178

UCA1 functions primarily as a competitive endogenous RNA (ceRNA) or 'miRNA sponge,' sequestering various microRNAs (e.g., miR-1, miR-143, miR-145) to prevent them from silencing their target oncogenic mRNAs. It also interacts directly with RNA-binding proteins such as BRG1 to modulate chromatin remodeling and transcriptional activity of genes like p21. Additionally, it activates oncogenic signaling pathways including PI3K/AKT, Wnt/beta-catenin, and MAPK/mTOR to promote cell survival and chemoresistance.